Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6967710 | 0.67 | CA1 (0.36) | CA1CA2FABP4FBP1 | |
| SCHEMBL4630683 | 0.64 | CA1 (0.36) | CA1CA2FABP4FBP1 | |
| SCHEMBL15203949 | 0.64 | TSHR (0.38) | — | |
| SCHEMBL8504959 | 0.62 | RAB9A (0.38) | CA1CA2FABP4 | |
| SCHEMBL6305096 | 0.62 | ACP3 (0.37) | — | |
| SCHEMBL4632383 | 0.61 | EDNRB (0.49) | CA1CA2 | |
| SCHEMBL1585204 | 0.60 | TSHR (0.41) | CA2 | |
| SCHEMBL15689486 | 0.59 | FDPS (0.40) | FBP1 | |
| SCHEMBL11763736 | 0.59 | PGK1 (0.42) | — | |
| SCHEMBL7870277 | 0.59 | PGK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRB, EDNRA, ECE2 | CA1 2160/4885CA2 972/4885FABP4 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.